{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-071379","form_type":"8-K","ticker":null,"cik":"0001567892","company_name":"Keenova Therapeutics plc","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.438328+00:00","generated_at":"2026-06-14T00:10:37.334004+00:00","sec_items":["2.04","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mallinckrodt skips interest on $1.025B notes, warns of possible Chapter 11","bullets":["Missed $650M 11.5% First Lien and $375M 10.0% Second Lien note interest due June 15, 2023.","Non-payment triggers 30-day grace period; event of default could accelerate all principal and interest.","Cross-default risk on first lien term loans and opioid settlement obligations if default not cured.","Board continues evaluating alternatives including Chapter 11 filing; no definitive decision made.","Made $16.5M payment to DOJ under Acthar Gel settlement despite liquidity constraints."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-071379","json":"https://secwatch.observer/filing/0001104659-23-071379.json","markdown":"https://secwatch.observer/filing/0001104659-23-071379.md","text":"https://secwatch.observer/filing/0001104659-23-071379.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923071379/0001104659-23-071379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923071379/tm2318768d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:10:37.334004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b0859f09b5cdb5fc7f1900e0765e3113f525f95","claim":"Keenova Therapeutics plc reported a default on senior notes of $375 million at 10.000% maturing due 2029.","evidence_excerpt":"per annum, is payable semi-annually in cash on June 15 and December 15 of each year. The 2029 Second Lien Notes were originally issued in an aggregate principal amount of $375 million on the Effective Date by the Issuers , and are guaranteed by, and secured by liens (which are junior in priority to the liens securing the Company’s first lien","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923071379/0001104659-23-071379-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$375 million"},{"label":"Rate","value":"10.000%"},{"label":"Maturity","value":"due 2029"},{"label":"Event","value":"default"}],"fact_type":"debt_financing"},{"claim_id":"efb89e9f25ff7f114284c62d00945dc2e80b8a5e","claim":"Keenova Therapeutics plc reported a default on senior notes of $650 million at 11.500% maturing due 2028.","evidence_excerpt":"and (ii) 10.000% Second Lien Senior Secured Notes due 2029 (the “2029 Second Lien Notes”). The 2028 First Lien Notes were originally issued in an aggregate principal amount of $650 million on June 16, 2022 (the “Effective Date”), by Mallinckrodt International Finance S.A. (“MIFSA”) and Mallinckrodt CB LLC (together with MIFSA, the “Issuers”), each of which is a","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923071379/0001104659-23-071379-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$650 million"},{"label":"Rate","value":"11.500%"},{"label":"Maturity","value":"due 2028"},{"label":"Event","value":"default"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}